Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 14, 2023; 29(10): 1551-1568
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1551
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1551
Table 1 Summary of phase 3 trials of sorafenib and lenvatinib for treatment of unresectable hepatocellular carcinoma
| Ref. | No. of patients (Child-Pugh A/B) | Treatment or placebo | Median OS in mo | Response rate, % | Control rate, % | Median TP in mo | Dose reduction, % patients | Discontinuation due to AE, % patients |
| Llovet et al[33] (SHARP) | 298 (284/14) | Sorafenib (400 mg × 2/d) | 10.7 | 2 | 43 | 5.5 | 26 | 11 |
| 303 (297/6) | Placebo | 7.9 | 1 | 32 | 2.8 | 7 | 5 | |
| Cheng et al[34] (Asia-Pacific) | 150 (146/4) | Sorafenib (400 mg × 2/d) | 6.5 | 3.3 | 35.3 | 5.5 | 30.9 | 19.5 |
| 76 (74/2) | Placebo | 4.2 | 1.3 | 15.8 | 2.8 | 2.7 | 13.3 | |
| Kudo et al[47] (REFLECT) | 478 (478/0) | Lenvatinib (12 mg/d) | 13.6 | 40.6 | 73.8 | 7.4 | 37 | 9 |
| 476 (476/0) | Sorafenib (400 mg × 2/d) | 12.3 | 12.4 | 56.4 | 3.7 | 38 | 7 |
- Citation: Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1551-1568
- URL: https://www.wjgnet.com/1007-9327/full/v29/i10/1551.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i10.1551